BioPharma Dive January 5, 2026
After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease and many rare conditions could help it continue.
For the first time in a while, the biotechnology industry starts a new year with momentum.
Large dealmaking has picked up, driving returns for public investors as well as the firms that form and build new drug startups. Multiple biotechs successfully grew sales of new medicines and, as a result, were rewarded with higher market values and lucrative stock offerings. In tandem, the...
Today's Sponsors
Today's Sponsor